Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn. , Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC) at a price of $3.10 per share in... Read More

JOHNSON CITY, Tenn. and NASHVILLE, Tenn. , Dec. 9, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, today announced that they have amended and restated the merger... Read More

On August 11, 2024, Revance and Crown Laboratories, Inc. entered into a merger agreement. As a result of discussions between the Revance and Teoxane, Crown and Revance agreed to extend the deadline upon which the tender offer must commence to November 12, 2024. The tender offer has not yet commenced. Revance entered into an amendment to the Exclusive Distribution Agreement with Teoxane for the distribution of the RHA®... Read More

Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY ® (toxin), the RHA ® Collection (filler), SkinPen ® (microneedling), PanOxyl ® (acne), Blue Lizard ® (sunscreen), and StriVectin ® (anti-aging) Opportunity for global commercialization capabilities with... Read More

Q2 total DAXXIFY® and RHA® (by Teoxane SA) product revenue of $65.3 million, a YoY increase of 20%. Q2 DAXXIFY net revenue of $28.7 million, a YoY increase of 27%. Q2 DAXXIFY aesthetic units sold increased 65% YoY and 15% QoQ; over 3,700 ordering accounts reached. Q2 RHA Collection net revenue of $36.6 million, a YoY increase of 15%. Revance launched DAXXIFY for cervical dystonia, with coverage with over 80% of commercial... Read More

Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. NASHVILLE, Tenn. / Aug 01, 2024 / Business Wire / Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to... Read More

NASHVILLE, Tenn. / Jun 14, 2024 / Business Wire / Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units (“RSUs”) to 31 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new employee's continued service... Read More

NASHVILLE, Tenn. / May 28, 2024 / Business Wire / Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin Schilke is scheduled to present on Tuesday, June 4, 2024, at 11:20 am CT, in Chicago, Illinois. Goldman Sachs 45th Annual Global Healthcare Conference President... Read More

Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. Toxin market share increased from 3.0% in Q4’23 to 3.7% in Q1’24. Aesthetic units sold increased 105% YoY and 7% QoQ, despite traditional seasonality. RHA® Collection net revenue of $29.6 million; filler market share... Read More

DAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to improve duration of symptom control 1 Revance has received a Permanent J-Code and has already secured coverage for 78% of commercial lives with top health plans, while also launching patient affordability programs Today’s launch provides first entry into the $2.7 billion U.S.... Read More

Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. NASHVILLE, Tenn. / May 02, 2024 / Business Wire / Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the... Read More

Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance NASHVILLE, Tenn. / Apr 12, 2024 / Business Wire / Revance Therapeutics, Inc. ( NASDAQ: RVNC), today announced two poster presentations on DAXXIFY® for the... Read More

NASHVILLE, Tenn. / Mar 27, 2024 / Business Wire / Revance Therapeutics, Inc . (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (“RSUs”) to 29 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new employee's continued service... Read More

NASHVILLE, Tenn. / Mar 04, 2024 / Business Wire / Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $6.25 per share. The gross proceeds from the public offering are expected to be $100.0 million, before deducting underwriting... Read More

NASHVILLE, Tenn. / Mar 04, 2024 / Business Wire / Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced a proposed underwritten public offering of $100 million of its common stock. In addition, the Company expects to grant the underwriter a 30-day option to purchase additional shares in an amount not to exceed 15% of the number of shares of common stock offered in the public offering. The... Read More

Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. Q4 DAXXIFY volume up 22% over Q3 2023, with over two-thirds of Q4 revenue attributable to reordering accounts. 2024 product revenue guidance of at least $280 million, supporting blockbuster potential in U.S. aesthetics. DAXXIFY for cervical dystonia on... Read More

Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET. NASHVILLE, Tenn. / Feb 21, 2024 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the... Read More

NASHVILLE, Tenn. / Feb 21, 2024 / Business Wire / Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences. Cowen 44 th Annual Healthcare Conference Chief Executive Officer, Mark Foley and Chief Financial Officer, Tobin Schilke are scheduled to participate in a fireside chat on Tuesday, March 5, 2024, at 12:50p.m. EST, in Boston, Massachusetts. Barclays... Read More

CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect and favorable safety profile NASHVILLE, Tenn. / Feb 02, 2024 / Business Wire / Revance Therapeutics, Inc. (RVNC) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J0589) for... Read More

NASHVILLE, Tenn. / Feb 01, 2024 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6 th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York. Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Thursday, February 8, at 9:30a.m. EST. Interested parties can access... Read More

Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. Preliminary unaudited Q4 and full year 2023 product revenue (DAXXIFY and RHA® Collection) of between $58 million and $59 million and $212 million and $213 million, representing approximately 28% and 80% YoY growth, respectively. Provides 2024 product revenue guidance of at least $280... Read More

Q3 total product revenue of $54.1 million, a YoY increase of 107.5%. Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million. Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%. In August, DAXXIFY was approved by the FDA for the treatment of cervical dystonia, representing the company's first approval in the therapeutics market. DAXXIFY cervical dystonia PrevU... Read More

NASHVILLE, Tenn. / Nov 08, 2023 / Business Wire / Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced the appointment of Erica Jordan, Senior Vice President of Commercial to Chief Commercial Officer (CCO), Aesthetics. As CCO, Erica will have global responsibility for all aesthetics commercial activity including commercial strategy, sales and marketing, branding, loyalty and engagement. “Given the importance of the... Read More

NASHVILLE, Tenn. / Nov 06, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences. Stifel 2023 Healthcare Conference Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, November 14, 2023, at 11:30 A.M. EST, in New York City, New York. Piper Sandler 35 th Annual Healthcare Conference... Read More

Conference Call Scheduled for Wednesday, November 8, 2023 at 4:30 p.m. ET NASHVILLE, Tenn. / Nov 01, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss... Read More

DAXXIFY® (daxibotulinumtoxinA-lanm) for Injection named to TIME’s list of the best inventions of 2023. DAXXIFY® is a long-lasting peptide enhanced neuromodulator that delivers the first true innovation in neuromodulator formulation in more than 30 years. NASHVILLE, Tenn. / Oct 26, 2023 / Business Wire / TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the... Read More

NASHVILLE, Tenn. / Sep 19, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC) announced that the company is hosting its Investor Day today, September 19, 2023, from 9:30 am ET to 12:00 pm ET. The Investor Day will include management presentations on Revance’s vision and strategy, Revance Aesthetics overview and launch progress, DAXXIFY® KOL panel, Revance Therapeutics commercial launch plans, future growth... Read More

NASHVILLE, Tenn. / Aug 22, 2023 / Business Wire / Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET. Interested parties can attend the live webcast for the event by registering on the Events and Presentation section of the company’s Investor Relations webpage. A webcast replay will be available beginning September 19,... Read More

Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market. 1 Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical study. DAXXIFY® for cervical dystonia is the first and only peptide-formulated, long-lasting neuromodulator, designed to meet the needs of patients seeking improved treatment outcomes. 2-5 88% of U.S. cervical dystonia patients... Read More

Q2 total revenue of $58.1 million, a YoY increase of 104.9%. Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%. Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%. Bolstered financial position with $100 million net proceeds from ATM program and $50 million in notes available to be issued through Athyrium Capital on or before August 31, 2023. PDUFA date of August 19, 2023 for DAXXIFY® for the... Read More

Conference Call Scheduled for Tuesday, August 8, 2023 at 4:30 p.m. ET. NASHVILLE, Tenn. / Aug 01, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will release second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the... Read More

NASHVILLE, Tenn. / May 23, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences. William Blair 43 rd Annual Growth Stock Conference Chief Executive Officer Mark J. Foley is scheduled to participate in a fireside chat on Tuesday, June 6, 2023, at 4:00 P.M. CDT, in Chicago, Illinois. Goldman Sachs 44 th Annual Global Healthcare... Read More

Q1 total revenue of $49.3 million, a YoY increase of 95.3%. Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%. Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU and March launch. FDA approves Ajinomoto Biopharma Services, Revance’s contract manufacturer for DAXXIFY®. Fosun Pharma’s BLA submission for DaxibotulinumtoxinA for Injection for glabellar lines accepted for review by China’s National Medical... Read More

Conference Call Scheduled for Tuesday, May 9, 2023 at 4:30 p.m. ET. NASHVILLE, Tenn. / May 02, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results... Read More

NASHVILLE, Tenn. / Apr 05, 2023 / Business Wire / Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22 nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, April 18, at 12:45 P.M. ET. Interested parties can access the live audio webcast for this... Read More

NASHVILLE, Tenn. / Mar 30, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced the release of its 2022 ESG Report, detailing the company’s progress towards its ESG priorities of innovation and access, workplace culture and strong corporate governance. The report was guided by the Sustainability Accounting Standards Board (SASB) framework. “In 2022, we delivered on our promise to bring meaningful... Read More

NASHVILLE, Tenn. / Mar 07, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences. Barclays Global Healthcare Conference Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Tuesday, March 14, at 9:00 A.M. ET, in Miami, Florida. Guggenheim Healthy Altitudes Summit Chief Financial Officer, Tobin... Read More

NASHVILLE, Tenn. / Feb 28, 2023 / Business Wire / Revance Therapeutics, Inc . (RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023. Dr. Coric brings more than 22 years of drug development and executive leadership experience to Revance based on his time at the Yale School of Medicine, Bristol-Myers Squibb, and Biohaven, which was acquired by Pfizer in 2022. The... Read More

NASHVILLE, Tenn. / Feb 28, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. Financial Highlights Total revenue for the fourth quarter 2022 was $49.9 million compared to $26.0 million for the same period last year, representing a 92% increase, primarily due to increased sales of the RHA... Read More

NASHVILLE, Tenn. / Feb 27, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43 rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachusetts. President, Dustin S. Sjuts, and Chief Financial Officer, Tobin Schilke, are scheduled to participate in a fireside chat on Monday, March 6, at 9:50 A.M. EST. Interested parties can access... Read More

NASHVILLE, Tenn. / Feb 23, 2023 / Business Wire / Revance Therapeutics, Inc . (RVNC) today announced that new data on DAXXIFY ® will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, February 21-24, 2023. The supplemental biologics license agreement for DAXXIFY® for the treatment of cervical dystonia is currently under regulatory review with the Food and... Read More

NASHVILLE, Tenn. / Feb 21, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals... Read More

DAXXIFY® PrevU program off to strong start with ~400 select practice partners and thousands of patients treated, generating positive feedback and strong, early uptake Preliminary unaudited Q4 DAXXIFY® revenue from PrevU of between $10.5 million and $11.5 million Preliminary unaudited Q4 RHA® Collection revenue of between $34.0 million and $35.0 million, a YoY increase of approximately 45% Aesthetic accounts across products... Read More

Prescription Drug User Fee Act (PDUFA) date of August 19, 2023 Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the... Read More